List of raw analysis data.

AIM Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an important treatment for blood disease, and ocular graft-versus-host disease (oGVHD) is a common complication that significantly affects the quality of life of patients. Currently, the risk factors for oGVHD are still controversial.Methods To provide a scientific foundation for the prevention of oGVHD in patients undergoing allo-HSCT, studies on the factors influencing the development of oGVHD were searched in PubMed, Embase, Web of Science, Sino Med, the Cochrane Library, CIKI, the Wanfang Database, and the VIP Database from database construction to May 2024.Results Seventeen studies included 4,501 patients who received allo-HSCT, of which 1,526 were diagnosed with oGVHD, involving 22 factors. The overall prevalence of oGVHD was 37.8%.[95% CI (0.294, 0.463)].The prevalence of oGVHD based on the diagnostic criteria recommended by the National Institutes of Health was 46.7% [95% CI (0.390, 0.545)], that of the International Chronic oGVHD Group was 33.7% [95% CI (0.167, 0.506)], and that of self-defined diagnostic criteria was 32.0% [95% CI (0.184, 0.457)]. According to the meta-analysis, elderly patients [OR=1.10, 95% CI (1.00, 1.20)], female donors [OR=1.48, 95% CI (1.20, 1.83)], matched-relative donors (MRD) [OR=1.50, 95% CI (1.22, 1.83)], peripheral hematopoietic stem cells (PBSCs) [OR=1.81, 95% CI (1.38, 2.39)], acute graft-versus-host disease (aGVHD) [OR=1.74, 95% CI (1.29, 2.35)], chronic graft-versus-host disease (cGVHD) [OR=3.04, 95% CI (1.82, 5.08)], oral [OR=13.83, 95% CI (5.09, 37.56)] and skin graft-versus-host disease (GVHD) [OR=5.55, 95% CI (2.41,12.79)] were risk factors for the development of oGVHD (P研究目的：异基因造血干细胞移植（allogeneic hematopoietic stem cell transplantation, allo-HSCT）是血液系统疾病的重要治疗手段，而眼部移植物抗宿主病（ocular graft-versus-host disease, oGVHD）是一类常见并发症，会显著降低患者的生活质量。目前，oGVHD的危险因素仍存在争议。 研究方法：为给接受allo-HSCT的患者预防oGVHD提供科学依据，本研究检索了PubMed、Embase、Web of Science、中国生物医学文献数据库（Sino Med）、Cochrane图书馆、中国知网（CNKI）、万方数据库（Wanfang Database）及维普数据库（VIP Database），检索时限为各数据库建库至2024年5月，检索主题为影响oGVHD发生发展的相关因素。 研究结果：本研究共纳入17项研究，涉及4501例接受allo-HSCT的患者，其中1526例被确诊为oGVHD，共分析了22个相关影响因素。oGVHD的总体患病率为37.8%[95%置信区间（CI）：0.294, 0.463]。 依据美国国立卫生研究院（National Institutes of Health, NIH）推荐的诊断标准统计的oGVHD患病率为46.7%[95%CI：0.390, 0.545]；依据国际慢性GVHD工作组（International Chronic oGVHD Group）的诊断标准统计的患病率为33.7%[95%CI：0.167, 0.506]；依据自行制定的诊断标准统计的患病率为32.0%[95%CI：0.184, 0.457]。 经荟萃分析结果显示，老年患者[比值比（OR）=1.10, 95%CI：1.00, 1.20]、女性供者[OR=1.48, 95%CI：1.20, 1.83]、相合亲属供者（matched-relative donors, MRD）[OR=1.50, 95%CI：1.22, 1.83]、外周血造血干细胞（peripheral hematopoietic stem cells, PBSCs）[OR=1.81, 95%CI：1.38, 2.39]、急性移植物抗宿主病（acute graft-versus-host disease, aGVHD）[OR=1.74, 95%CI：1.29, 2.35]、慢性移植物抗宿主病（chronic graft-versus-host disease, cGVHD）[OR=3.04, 95%CI：1.82, 5.08]、口腔GVHD[OR=13.83, 95%CI：5.09, 37.56]及皮肤移植物抗宿主病[OR=5.55, 95%CI：2.41, 12.79]均为oGVHD发生的危险因素（P